证券代码：001300 证券简称：三柏硕 公告编号：2025-013 青岛三柏硕健康科技股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第二届董事会第八 次会议于 2025 年 4 月 25 日以现场和通讯方式召开，会议通知于 2025 年 4 月 15 日以专人送达、通讯、邮件等形式送达。会议应出席董事 7 名，实际出席董事 7 名。公司董事长朱希龙先生主持本次会议。会议的召集、召开符合《中华人民共 和国公司法》等法律法规及《青岛三柏硕健康科技股份有限公司章程》的规定。 公司监事、高级管理人员列席本次会议。 与会董事对本次会议的全部议案进行了充分讨论，审慎表决，形成如下决议： 一、审议通过：《2024 年年度报告及其摘要》 表决情况：7票同意，0票反对，0票弃权。 具体内容详见公司同日刊登在《证券时报》《证券日报》《中国证券报》《上 海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）的《2024 年年度 报告》《2024 年年度报告摘要》（ ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-015 青岛三柏硕健康科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 审议程序 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年4月25日 分别召开了第二届董事会第八次会议及第二届监事会第八次会议，审议通过《关 于2024年度利润分配预案的议案》，该议案尚需提交公司2024年年度股东大会审 议。 二、2024年度利润分配预案基本情况 经和信会计师事务所（特殊普通合伙）审计，公司2024年度实现归属于上市 公司股东的净利润22,269,198.00元，母公司实现净利润37,597,214.25元，根据《公 司法》和《公司章程》规定，提取法定盈余公积3,759,721.43元。截至2024年12月 31日，公司合并报表可分配利润为167,443,170.10元，母公司可分配利润为 177,398,895.33元。根据利润分配应以母公司的可供分配利润及合并财务报表的 可供分配利润孰低的原则，截至2024年12月31日公司可供股东 ...

Financial Performance - The company's operating revenue for 2024 reached ¥551,843,636.01, representing a 66.14% increase compared to ¥332,147,746.38 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥22,269,198.00, a significant turnaround from a loss of ¥42,937,284.83 in 2023, marking a 151.86% improvement[6]. - The cash flow from operating activities increased by 355.19% to ¥21,056,572.48 in 2024, compared to ¥4,625,850.42 in 2023[6]. - Basic earnings per share for 2024 were ¥0.0914, up 151.90% from a loss of ¥0.1761 in 2023[6]. - Total assets at the end of 2024 were ¥1,316,149,336.10, reflecting a 9.75% increase from ¥1,199,263,425.05 at the end of 2023[6]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching ¥11,537,274.30 in 2024, compared to a loss of ¥52,900,628.30 in 2023, a 121.81% improvement[6]. - The company's total revenue for 2024 reached ¥551,843,636.01, representing a 66.14% increase compared to ¥332,147,746.38 in 2023[61]. - The trampoline segment generated ¥183,848,615.10, accounting for 33.32% of total revenue, with a year-on-year growth of 40.03%[61]. - Fitness equipment sales surged by 108.52%, totaling ¥188,258,985.11, which represents 34.11% of total revenue[61]. - The North American market contributed ¥188,069,086.06, a 49.35% increase from ¥125,923,078.71 in the previous year[61]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.10 RMB per 10 shares to all shareholders, based on a total of 242,480,914 shares[6]. - The company reported a cash dividend of ¥0.10 per 10 shares (including tax), totaling a cash dividend distribution of ¥2,424,809.14, which represents 100% of the total profit distribution[157][159]. - The distributable profit for the reporting period was ¥167,443,170.10[157]. Business Operations and Strategy - The company is positioned in the sports goods manufacturing industry, focusing on leisure sports and fitness equipment[32]. - The company focuses on the research, design, production, and sales of leisure sports and fitness equipment, with a product portfolio of approximately 31 series and over 1,000 products[45]. - The company has established stable partnerships with international retailers and sports brands, including Decathlon, Walmart, and Amazon, enhancing its market presence[52]. - The company is committed to continuous technological innovation and product development, aiming to strengthen its position as a leader in the trampoline sector[45]. - The company is currently developing a new easy-install basketball hoop to enhance product competitiveness and brand influence in the market[72]. - A new foldable trampoline is under development, aimed at capturing market demand and enhancing product competitiveness for long-term growth[72]. - The company is working on a home fitness series that combines multiple functions and is designed for easy storage, targeting the growing home fitness market[72]. - Development of a smart running machine suitable for home use is ongoing, which aims to meet diverse fitness needs and strengthen the company's technological leadership in the fitness equipment industry[72]. - The company is also focusing on developing a waterproof and durable table tennis table to enhance user experience and extend product lifespan[72]. - A modular training combination device is being developed to cater to various training needs, which is expected to enrich the product range and enhance market competitiveness[72]. Market Trends and Industry Insights - Recent government policies aim to enhance the fitness equipment industry, promoting public sports services and expanding facility supply[33]. - The fitness equipment industry in China had a business climate index of 152.9, indicating a strong market performance driven by sustained household fitness demand and the recovery of commercial gym markets[38][39]. - The trampoline industry in China is experiencing growth due to policy support and increased health awareness, with trampolines becoming popular for home fitness and family entertainment[41]. - The global trampoline market is expected to recover in 2024 as consumer spending on non-essential items increases, following a period of economic fluctuation[40]. - The integration of smart devices and online courses is accelerating the trend of home workouts, creating new opportunities for the fitness industry[42]. - The industry is shifting towards smart and professional products, with consumers increasingly valuing intelligent interaction and personalized fitness solutions[43]. - The children's and elderly fitness markets are expanding simultaneously, driven by rising health awareness and the aging population, creating a dual growth engine[44]. - Cross-border e-commerce is opening global sales channels for the sports goods industry, although challenges such as domestic competition and international barriers remain[44]. Research and Development - The company’s R&D capabilities are supported by a comprehensive technical system that covers the entire chain from research to market application, enabling rapid product development[53]. - Research and development (R&D) investment amounted to CNY 23.997 million in 2024, reflecting a 5.58% increase from CNY 22.728 million in 2023[74]. - The proportion of R&D investment to operating revenue decreased from 6.84% in 2023 to 4.35% in 2024 due to the significant revenue increase[75]. - The company expanded its R&D personnel to 93 in 2024, a 3.33% increase from 90 in 2023[74]. - The number of R&D personnel with a master's degree rose by 12.50% from 8 in 2023 to 9 in 2024[74]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operation from controlling shareholders[117]. - The company has a complete financial accounting system and does not share bank accounts with controlling shareholders, ensuring financial independence[121]. - The company has a comprehensive business system and operates independently from its controlling shareholders, with no significant related party transactions[123]. - The company maintains a high level of transparency and compliance in its governance practices, with no significant discrepancies from regulatory requirements[117]. - The company has established a complete organizational structure and internal management system to support its independent operations[122]. - The company has successfully conducted multiple shareholder meetings, with resolutions passed in accordance with legal procedures[125]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,031, with 443 in the parent company and 588 in major subsidiaries[151]. - The professional composition includes 680 production personnel, 66 sales personnel, and 62 technical personnel[151]. - The company provides various employee benefits, including meal allowances, free shuttle buses, and team-building activities, in addition to mandatory social insurance[153]. - The company has established a performance execution mechanism based on its operational philosophy and strategic goals, ensuring competitive salary levels through annual salary surveys[153]. Financial Management and Investment - The company has implemented a fundraising management system to ensure effective control over the use of raised funds, with no violations reported during the reporting period[174]. - The financial department is responsible for the financial management of investment projects, ensuring compliance with relevant regulations[172]. - The company has established an investment management system to regulate investment activities, covering production, non-production, equity investments, and others[171]. - The company has committed to a production project for trampoline manufacturing, with an expected completion date in 2024 and an investment of 6.37 million[92]. - A new research and development center project is underway, with an investment of 8.20 million and a projected completion date in 2026[92]. Risk Management - The company faces risks from international trade policy changes, high reliance on overseas markets, and increasing competition, and is implementing strategies to mitigate these risks[108][110][111]. - The company is monitoring foreign exchange fluctuations closely to manage risks associated with its predominantly overseas sales[112]. Environmental and Social Responsibility - The company has obtained various environmental permits, including a wastewater discharge permit valid until July 18, 2028[199]. - The company has implemented measures to reduce carbon emissions, ensuring compliance with environmental standards[199]. - The company emphasizes the protection of creditor rights and adheres to relevant laws and agreements in credit cooperation[200]. - The company has established a commitment to providing fair working conditions and career development opportunities for employees[200].

Financial Performance - The company's revenue for Q1 2025 was ¥138,409,098, a decrease of 12.34% compared to ¥157,895,723 in the same period last year[5] - Net profit attributable to shareholders was ¥6,526,018, down 46.61% from ¥12,223,697 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥4,087,618, reflecting a decline of 56.61% from ¥9,421,464 in the same period last year[5] - Total operating revenue decreased to ¥138,409,098 from ¥157,895,723.53, a decline of approximately 12.3% year-over-year[18] - Net profit for the period was ¥6,527,432.22, down from ¥12,223,697.03, representing a decrease of approximately 46.5% year-over-year[19] - Earnings per share (basic and diluted) decreased to ¥0.0268 from ¥0.0501, a decline of about 46.5%[19] Cash Flow and Investments - The net cash flow from operating activities improved by 48.13%, reaching -¥15,872,432 compared to -¥30,598,207 in the previous year[5] - Cash inflow from investment activities totaled $756.54 million, significantly up from $382.62 million in the previous period[22] - Cash outflow from investment activities was $782.61 million, compared to $518.62 million last year, resulting in a net cash flow from investments of -$26.07 million[22] - Financing activities generated a net cash inflow of $9.06 million, reversing from a net outflow of -$0.92 million in the previous period[23] - The company's cash and cash equivalents decreased by $32.63 million, ending the period with a balance of $219.30 million[23] - Cash inflow from sales of goods and services was $133.49 million, up from $84.90 million year-over-year[22] - Cash received from tax refunds increased to $9.41 million, compared to $8.74 million in the previous period[22] - Total cash outflow for operating activities was $160.93 million, compared to $126.06 million last year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,271,133,243.89, a decrease of 3.42% from ¥1,316,149,336.10 at the end of the previous year[5] - Current assets total 1,024,620,517.71 RMB, a decrease from 1,062,964,735.76 RMB in the previous period[16] - Total liabilities decreased to ¥217,541,209.74 from ¥260,536,279.33, a reduction of approximately 16.5%[17] - Total equity attributable to shareholders decreased to ¥1,050,590,620.10 from ¥1,055,613,056.77, a slight decline of about 0.5%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,651[11] - The largest shareholder, Qingdao Haishuo Health Industry Development Co., Ltd., holds 47.30% of shares, totaling 115,317,531 shares[11] - The company has a total of 19.52% shares held by J.LU INVESTMENTS LLC, amounting to 47,583,346 shares[11] - The company has repurchased a total of 1,295,000 shares, accounting for 0.53% of the total share capital, with a total transaction amount of 15,780,745.00 RMB[13] Operational Highlights - The company reported a significant increase in short-term borrowings, rising by 178.62% to ¥27,609,277.77 from ¥9,909,277.77[8] - The company experienced a 63.56% increase in taxes and additional charges, totaling ¥1,360,419.31 compared to ¥831,769.57 in the previous year[8] - The company has not reported any new product developments or market expansion strategies in this quarter[5] - The company reported a financial expense of -¥1,499,434.36, compared to -¥1,445,861.31 in the previous period, indicating a slight increase in financial costs[18] - Other comprehensive income after tax decreased to -¥110,037.11 from ¥729,213.02, indicating a significant decline in this area[19]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2024年4月26日 分别召开第二届董事会第三次会议及第二届监事会第三次会议，审议通过《关于 使用部分闲置募集资金暂时补充流动资金的议案》，同意公司及子公司在确保不 影响募投项目正常实施的前提下，结合实际经营需求和财务状况，使用不超过人 民币1.5亿元的闲置募集资金暂时补充流动资金，使用期限自公司董事会审议通 过之日起不超过12个月，到期归还至募集资金专户。在上述额度及期限内，资金 可循环滚动使用。具体内容详见公司刊登在《证券时报》《证券日报》《中国证 券报》《上海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）的《关 于使用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2024-019）。 截至本公告日，公司未使用闲置募集资金暂时补充流动资金。公司已将上述 情况通知了公司保荐机构及保荐代表人。 特此公告。 证券代码：001300 证券简称：三柏硕 公告编号：2025-011 青岛三柏硕健康科技股份有限公司 关于提前归还暂时补充流动 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"或"三柏硕"）于2024年4月26日召开第二届董事会 第三次会议、第二届监事会第三次会议，于2024年5月28日召开2023年年度股东大会，审议通过了《关 于延长使用部分暂时闲置募集资金进行现金管理的授权期限的议案》，同意在确保不影响募集资金投资 计划正常进行和募集资金安全的情况下，公司及全资子公司使用额度不超过5亿元人民币的部分暂时闲 置募集资金进行现金管理。授权期限自2023年年度股东大会通过之日起至2024年年度股东大会召开之 日，单个投资产品的投资期限不超过12个月。额度范围内资金可循环滚动使用。具体内容详见公司于 2024年4月27日披露的《关于延长使用部分暂时闲置募集资金进行现金管理的授权期限的公告》（公告 编号：2024-027）。 1、虽然公司对拟投资理财产品都执行严格的风险评估，但金融市场受宏观经济等因素影响，不排除上 述投资受到市场波动的影响； 2、公司将根据经济形势以及金融市场的变化适时适量介入 ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-010 青岛三柏硕健康科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"或"三柏硕"）于2024 年4月26日召开第二届董事会第三次会议、第二届监事会第三次会议，于2024年5 月28日召开2023年年度股东大会，审议通过了《关于延长使用部分暂时闲置募 集资金进行现金管理的授权期限的议案》，同意在确保不影响募集资金投资计 划正常进行和募集资金安全的情况下，公司及全资子公司使用额度不超过5亿元 人民币的部分暂时闲置募集资金进行现金管理。授权期限自2023年年度股东大 会通过之日起至2024年年度股东大会召开之日，单个投资产品的投资期限不超 过12个月。额度范围内资金可循环滚动使用。具体内容详见公司于2024年4月27 日披露的《关于延长使用部分暂时闲置募集资金进行现金管理的授权期限的公告》 （公告编号：2024-027）。 根据上述决议，公司近期使用闲置募集资金（含现金管理收益和募集资金 ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-009 青岛三柏硕健康科技股份有限公司 关于回购股份方案实施完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2024年3月8日召开 第二届董事会第二次会议、第二届监事会第二次会议，于2024年3月25日召开2024 年第一次临时股东大会，审议通过了《关于回购公司股份方案的议案》。公司使 用自有资金以集中竞价交易方式回购公司部分人民币普通股A股股份，用于员工 持股计划或者股权激励，回购资金总额不低于人民币1,500万元（含）且不超过 3,000万元（含）。回购价格不超过人民币20.00元/股，回购股份的实施期限自 股东大会审议通过本次回购股份方案之日起不超过12个月。为进一步提升资金使 用效率，充分利用国家对上市公司回购股票的支持政策，综合考虑公司业务发展、 资金储备及资金使用规划等情况，公司于2025年2月13日分别召开第二届董事会 第七次会议、第二届监事会第七次会议，审议通过了《关于调整回购股份方案的 议案》，同意将回购股份 ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-008 青岛三柏硕健康科技股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2024年3月8日召开 第二届董事会第二次会议、第二届监事会第二次会议，于2024年3月25日召开2024 年第一次临时股东大会，审议通过了《关于回购公司股份方案的议案》。公司使 用自有资金以集中竞价交易方式回购公司部分人民币普通股A股股份，用于员工 持股计划或者股权激励，回购资金总额不低于人民币1,500万元（含）且不超过 3,000万元（含）。回购价格不超过人民币20.00元/股，回购股份的实施期限自 股东大会审议通过本次回购股份方案之日起不超过12个月。具体内容详见公司刊 登在《证券时报》《证券日报》《中国证券报》《上海证券报》《经济参考报》 和巨潮资讯网（www.cninfo.com.cn）的《关于回购公司股份方案的公告》（公 告编号：2024-005）。 为进一步提升资金使用效率，充分利用国家对上市公司回购股票的支持政策， ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-006 表决情况：3票同意，0票反对，0票弃权。 经审核，监事会认为：本次调整回购股份方案中回购股份资金来源有利于提 高资金使用效率，降低公司融资成本，确保回购股份方案的顺利实施，符合相关 法律法规的规定。上述事项不会对公司当年的经营业绩产生重大影响，亦不存在 损害公司及全体股东，特别是中小股东利益的情形。监事会同意该事项。 具体内容详见公司同日刊登在《证券时报》《证券日报》《中国证券报》《上 海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）的《关于调整回 购股份方案暨取得金融机构回购专项贷款承诺函的公告》（公告编号：2025-007）。 二、备查文件 青岛三柏硕健康科技股份有限公司 第二届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第二届监事会第七 次会议于 2025 年 2 月 13 日在公司会议室以现场方式召开，会议通知于 2025 年 2 月 7 日以专人送达、邮件等形式发出。会议应出 ...